Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of ZP5-9676 for soil-transmitted helminth infections
PACTR202404505131714Phase 3Not yet recruiting
- Sponsor
- Zero Point Five Therapeutics
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in Soil-Transmitted Helminthiases (STH), hookworm infection, ascariasis and 1 more comparing ZP5-9676 with Placebo (2 arms). Primary endpoint: Cure rates for each soil-transmitted helminth. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
ZP5-9676
03
Conditions
Soil-Transmitted Helminthiases (STH)hookworm infectionascariasistrichuriasis
Beyond the preview
Go deeper on PACTR202404505131714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202404505131714.